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Abstract
Background: High score of model for end-stage liver diseases (MELD) before liver transplantation (LT) indicates poor
prognosis. Artificial liver support system (ALSS) has been proved to effectively improve liver and kidney functions, and thus
reduce the MELD score. We aim to evaluate whether downgrading MELD score could improve patient survival after LT.
Methodology/Principal Findings: One hundred and twenty-six LT candidates with acute-on-chronic hepatitis B liver failure
and MELD score $30 were included in this prospective study. Of the 126 patients, 42 received emergency LT within 72 h
(ELT group) and the other 84 were given ALSS as salvage treatment. Of the 84 patients, 33 were found to have reduced
MELD score (,30) on the day of LT (DGM group), 51 underwent LT with persistent high MELD score (N-DGM group). The
median waiting time for a donor was 10 for DGM group and 9.5 days for N-DGM group. In N-DGM group there is a
significantly higher overall mortality (43.1%) than that in ELT group (16.7%) and DGM group (15.2%). N-DGM (vs. ECT and
DGM) was the only independent risk factor of overall mortality (P=0.003). Age .40 years and the interval from last ALSS to
LT .48 h were independent negative influence factors of downgrading MELD.
Conclusions/Significance: Downgrading MELD for liver transplant candidates with MELD score $30 was effective in
improving patient prognosis. An appropriate ALSS treatment within 48 h prior to LT is potentially beneficial.
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Introduction
One-third of global individuals infected with hepatitis B virus
(HBV) reside in China, with 130 million carriers, 30 million
chronically infected, and 300 thousand per year HBV-related
deaths [1–3]. Because of the high prevalence of hepatitis B, acute
exacerbation of chronic hepatitis B and acute deterioration of
cirrhosis are the most common causes of liver failure, contributing
to especially high mortality in China. Most recently, these types of
liver failure has been considered as acute-on-chronic liver failure
(ACLF), which was clearly defined by Asian Pacific Association for
the Study of the Liver as ‘acute hepatic insult manifesting as
jaundice and coagulopathy, complicated within 4 weeks by ascites
and/or encephalopathy in a patient with previously diagnosed or
undiagnosed chronic liver disease’ [4]. When ACLF progresses to
multi-organ dysfunction such as hepatorenal syndrome and
hepatic encephalopathy, the prognosis is dismal unless liver
transplantation (LT), the only definitive therapy to salvage these
patients, is performed [4]. Since model for end-stage liver diseases
(MELD) score was used for organ allocation, candidates with
ACLF have the priority to gain the donor liver and receive
emergency LT because patients with ACLF usually have high
MELD score [5,6]. However, ‘high-grade’ ($30) MELD scores in
ACLF indicate poorer prognosis after liver support treatment even
LT [6–8]. For ACLF patients with MELD score$30, the 30-day
survival was less than 10% after ALSS salvage [7], and the 1-year
survival after LT was much lower than that of patients with
MELD score ,30 (33.3% vs. 77.8%) [9]. Thus when the MELD
score is ,30 it may be the optimal time to perform LT for patients
with ACLF [9].
Artificial liver support system (ALSS) has been proved to be an
effective way to improve liver function and thus serve as a bridge
to LT [10]. After such treatment, total bilirubin, international
normalized ratio, encephalopathy, and serum creatinine can be
remarkably improved and thus MELD score was reduced [11].
According to the treatment guidelines for ALSS formulated by
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Parasitic Diseases and Chinese Medical Association [12], the
management of ACLF patients were principally supportive with
ALSS treatment prior to LT. In this study, we performed ALSS to
salvage ACLF patients with ‘high-grade’ MELD score. We aim to
evaluate whether downgrading pre-transplant MELD score could
improve patient survival after LT, and to determine the possible
influence factors of downgrading MELD.
Methods
Patient characteristics
A total of 189 adult patients with acute-on-chronic hepatitis B
liver failure (ACLF-HBV) underwent primary LT between
January 2001 and June 2010 at the First Affiliated Hospital,
Zhejiang University School of Medicine, China. Informed consent
was obtained from all donors and recipients before LT. Each
organ donation or transplant in our centre was strictly selected
according to the guidelines of the Ethical Committee of our
hospital, the regulation of Organ Transplant Committee of
Zhejiang province and the Declaration of Helsinki. Of the 189
liver transplant candidates, 126 (113 male and 13 female)
representing MELD score $30 in the waiting list were enrolled
in this prospective study. The study protocol was approved by the
Ethics Committee, and written informed consent was obtained
from all study patients. Recipients with liver cancer were excluded
from the study population. Patient characteristics were summa-
rized in Table S1.
All patients received lamivudine combined with low-dose
intramuscular hepatitis B immunoglobulin therapy according to
our anti-virus protocol [13]. All patients were given standard
medical treatments including energy supplements, intravenous
infusion of albumin and plasma, and preventive treatment of
complications. Of the 126 patients, 42 gained prompt donor livers
and received emergency LT without any prior treatment (ELT
group), the other 84 were given ALSS treatment before LT. The
84 patients were further divided into two sub-groups according to
the MELD score on the day of transplant: decreased MELD group
(DGM group, n=33) (MELD score decreased to a level of ,30)
and non-decreased MELD group (N-DGM group, n=51)
(persistent high MELD score $30).
There are indications for ACLF patients receiving ALSS
treatment according to Artificial Liver Group, Chinese Association
of Infectious and Parasitic Diseases and Chinese Medical
Association [12]. The methods of ALSS included plasma exchange
with or without continuous hemodiafiltration or plasma perfusion,
and molecular adsorbents recirculating system, as described
previously [14]. The specialists from Infectious Diseases Depart-
ment chose therapies and carried out ALSS treatment 1–3 times
per week based on the condition of patients and the facility
(availability of plasma or machine). The decision to initiate
hemodiafiltration were made by consultant nephrologists to
prevent uremia or immediate death from the adverse complica-
tions of renal failure [15]. In principle, patients with coagulopathy
were indicated for plasma exchange (PE); patients with hepatic
encephalopathy were given PE plus plasma perfusion or
continuous hemodiafiltration. For patients complicated with
hepatorenal syndrome or water – electrolytes imbalance, we
applied PE plus continuous hemodiafiltration or molecular
adsorbents recirculating system. In DGM group, 106 sessions of
ALSS were applied to 33 patients with PE 61 times, PE plus
plasma perfusion 21 times, PE plus continuous hemodiafiltration
14 times and molecular adsorbents recirculating system 10 times.
In N-DGM group, 149 sessions of ALSS were applied to 51
patients, with PE 69 times, PE plus plasma perfusion 39 times, PE
plus continuous hemodiafiltration 20 times and molecular
adsorbents recirculating system 21 times. Emergency LT was
performed within 72 h after patients became LT candidates for
the purpose of our protocol [16].
United Network for Organ Sharing status was used to stratify
the patients on the waiting list and allocate donor organs before
December 2002, and then substituted by MELD score after
January 2003. Post-reperfusion liver biopsies were obtained after
liver implantation for histological evaluation of donor liver
steatosis. According to the grade of macrovesicular steatosis, liver
grafts were categorized into four groups: no steatosis, mild steatosis
(,30%), moderate steatosis (30–60%), and severe steatosis (.60%)
[17]. Deceased donor liver transplantation (DDLT) and living
donor liver transplantation (LDLT) were performed in 93 and 33
cases, respectively. Of 93 donations after cardiac death, 3 were
controlled and 90 were uncontrolled. Operation techniques of
both DDLT and LDLT were described previously [18,19]. The
primary immunosuppressive regimen was triple therapy incorpo-
rating tacrolimus or cyclosporine, mycophenolate and steroid [20].
An IL-2 receptor blocker was used in selected patients.
Data collection
All patients were followed up closely in the outpatient clinic and
data were collected for analysis. Pre-transplant data included age,
gender, underlying liver disease, complications, MELD score,
serum potassium and sodium, need for ALSS, and need for
intensive care. Post-transplant complications, organ function and
patient survival were also collected.
MELD was calculated according to the UNOS formula:
MELD=3.786ln (bilirubin [mg/dl])+9.576ln (creatinine [mg/
dl])+11.206ln (international normalized ratio)+6.43 and the range
of the MELD score is 6–40 [21]. Delta-MELD=MELD score
calculated on the day of transplant2MELD score calculated when
patients were listed as LT candidates. The post-transplant model
for predicting mortality (PMPM) score was calculated at 24 h
following transplantation: PMPM score=25.359+1.9886ln (se-
rum creatinine [mg/dl])+1.0896ln (total bilirubin [mg/dl]) [22].
According to Asian Pacific Association for the Study of the
Liver, ACLF was defined as ‘acute hepatic insult manifesting as
jaundice (serum bilirubin .5 mg/dl) and coagulopathy (interna-
tional normalized ratio .1.5 or prothrombin time activity ,40%),
complicated within 4 weeks by ascites and/or encephalopathy in a
patient with previously diagnosed or undiagnosed chronic liver
disease’ [4]. The diagnosis of acute exacerbation of chronic
hepatitis B was based on findings of fibrous bands and ductular
proliferation using by biopsy [4]. The diagnosis of cirrhosis with
acute deterioration was based on the presence of hepatocyte
necrosis and features of acute hepatitis under the background of
cirrhosis [4]. The diagnostic criteria for hepatorenal syndrome was
based on the International Ascites Club consensus [23]. The
diagnosis of hepatic encephalopathy was based on the clinical
manifestations and the signs of brain edema. The severity of
hepatic encephalopathy was evaluated by the criteria for grading
mental status [14]. Early allograft dysfunction was defined by the
presence of at least one of the following characteristics: total
bilirubin .10 mg/dl, prothrombin time $17 s and hepatic
encephalopathy from days 2 to 7 post-transplantation [24]. Acute
kidney injury was defined as an elevated level of serum creatinine
(.1.5 mg/dL) or/and need for hemodiafiltration during the first
post-transplant week [25]. Acute rejection was diagnosed routinely
in liver biopsies according to the Rejection Activity Index criteria.
Bacterial and fungus infection was diagnosed on the basis of
primary culture, while viral infection was diagnosed on the basis of
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classified as bile leakage and stenosis. Bile leakage was primarily
diagnosed on the basis of bilirubin in abdominal drainage, newly
inserted pigtail, or cholangiography. Biliary stenosis was diagnosed
on the basis of an overt dilatation of the intra-hepatic duct
according to the imaging findings.
Statistical methodology
The Kolmogorov-Smirnov test was used to evaluate normality.
Quantitative variables were presented as mean 6 SD. Categorical
variables were expressed as values and percentages. Student’s t test
or Mann-Whitney test was used to compare quantitative variables,
while Chi-square test was used to compare categorical variables.
Kaplan-Meier method with log-rank test and COX regression
analysis were used for survival analysis. Logistic regression analysis
was used for influence factors analysis. Variables with statistically
significance in univariate analysis were taken for a forward
stepwise multivariate analysis. SPSS for Windows version 11.0
(SPSS Inc., Chicago, IL) was used to complete all the analyses, and
a P value of ,0.05 was considered statistically significant.
Results
Pre-transplant ALSS treatment
The liver and kidney functions were improved temporarily after
each ALSS session in all treated patients, presenting a significantly
decreasesintotal bilirubin (33.4612.7 mg/dLvs.16.369.7 mg/dL,
P,0.001), alanine aminotransferase (1696135 U/L vs. 78667 U/
L, P=0.012), aspartate aminotransferase (2026107 U/L vs.
101680 U/L, P,0.001), prothrombin time (32.6610.3 s vs.
21.566.4 s, P=0.024), international normalized ratio (3.3660.95
vs. 2.1760.76, P=0.018) and serum creatinine (2.0461.04 mg/dL
vs. 1.2160.83 mg/dL, P=0.041). However, after all sessions of
ALSS treatment, DGM group showed better liver and kidney
functions than N-DGM group (Table 1).
Complications which occurred in 31 patients (24.6%) during
ALSS therapy included skin rash (11.1%), hypotension (6.3%),
blood coagulation in perfusion cartridges (3.2%), local bleeding
(3.2%) and infection (2.4%).
The median interval time from the last ALSS treatment to LT
was 48 h (range: 24 h–8 d) in DGM group and 72 h (24 h–25 d)
in N-DGM group (P=0.147). The median waiting time for a
donor liver was 10 days (range: 4–43 d) in DGM group and 9.5
days (range: 4–70 d) in N-DGM group, (P=0.792).All recipients
and donors experienced uneventful operative procedure.
Post-transplant complications
The incidence of post-transplant hemorrhage, early allograft
dysfunction, acute kidney injury, acute rejection, infection and
biliary complication was 10.3%, 28.6%, 15.9%, 12.7%, 29.4%
and 13.5%, respectively. Most of complications (82.4%) developed
in the first post-transplant month. In N-DGM group there was a
significantly higher prevalence of acute kidney injury than that in
ELT group (39.2% vs. 14.3%, P=0.008) and DGM group (39.2%
vs. 9.1%, P=0.002), and higher incidence of infection than that in
ELT group (43.1% vs. 19.0%, P=0.013) and DGM group (43.1%
vs. 21.2%, P=0.039).
Patient survival
Of all 126 patients, 34 passed away during a median of 1.53
(0.03–9.86) years follow-up (Figure 1). The 1-month, 1-year and
5-year mortality was 16.7%, 24.6% and 27.0%, respectively, in the
whole study population. There was a significantly higher overall
mortality in N-DGM group than that in ELT group (43.1% vs.
16.7%, P=0.007) and DGM group (43.1% vs. 15.2%, P=0.006).
Most of deaths (21/34) occurred during the first post-transplant
month. The causes of early death (,30 d) were multi-organ
dysfunction syndrome (MODS, n=15), hemorrhage (n=4) and
infection (n=2). The early mortality was 14.3%, 9.1%, and 23.5%
in the ELT group, DGM group and N-DGM group, respectively.
Patient cumulative survivals were presented in Figure 2 and
did not differ significantly between patients undergoing LDLT and
those receiving DDLT (P=0.338), patients with acute exacerba-
tion of chronic hepatitis B and those with acute deterioration of
cirrhosis (P=0.655), or DGM group and ELT group (P=0.901).
There was a significantly lower patient cumulative survival in N-
DGM group than that in NDM group (P=0.008) and ELT group
(P=0.006). Patients with PMPM score ,21.4 had a remarkably
higher cumulative survival than those with PMPM score .21.4
(P,0.001).
Risk factors of death
Univariable analysis showed the following pre-transplant factors
that were significantly related to the early death (,30 d): N-DGM
(vs. ECT and DGM), delta-MELD, hepatorenal syndrome,
infection, and serum sodium. These factors were then entered
into the multivariable COX analysis and the independent risk
factors of early death were N-DGM (vs. ECT and DGM)
(RR=2.426, P=0.049) and hepatorenal syndrome (RR=2.422,
P=0.039) (Table 2).
N-DGM (vs. ECT and DGM), delta-MELD, hepatorenal
syndrome and serum sodium were found significantly associated
with overall death, however, only N-DGM (vs. ECT and DGM)
Table 1. Changes of biochemistry parameters after all
sessions of ALSS treatment.
DGM group N-DGM group
(n=33) (n=51)
Total bilirubin
On the day of listing 28.4611.8 26.6610.2
On the day of transplant* 19.668.6 29.2612.4
Alanine aminotransferase
On the day of listing 1326123 1486102
On the day of transplant* 67646 169697
Aspartate aminotransferase
On the day of listing 1956112 202696
On the day of transplant* 98676 2136105
Prothrombin time
On the day of listing 28.4611.2 30.1610.6
On the day of transplant* 20.267.3 31.269.8
International normalized ratio
On the day of listing 2.860.9 2.961.1
On the day of transplant* 2.160.7 3.061.2
Serum creatinine
On the day of listing 1.260.6 1.561.0
On the day of transplant* 1.160.7 1.761.1
Abbreviations: ALSS, artificial liver support system; DGM, downgraded MELD;
MELD, model for end-stage liver disease; N-DGM, non-downgraded MELD;
*: N-DGM group vs. DGM group, P,0.05;
doi:10.1371/journal.pone.0030322.t001
Downgrading MELD Improves the Outcomes after LT
PLoS ONE | www.plosone.org 3 January 2012 | Volume 7 | Issue 1 | e30322(RR=3.209, P=0.003) was the independent risk factor of overall
death (Table 2).
Influence factors of downgrading MELD
Compared with DGM group, N-DGM group showed older age,
more hepatic encephalopathy, more hepatorenal syndrome, and
more infection (Table 3). Logistic regression univariable analysis
demonstrated age .40 y, hepatic encephalopathy, hepatorenal
syndrome, infection and the interval from last ALSS to LT .48 h
were negative influence factors of downgrading MELD. Then
these factors were entered into multivariable analysis and the
independent negative factors influencing the reduction of MELD
were age .40 y (OR=0.240, P=0.015) and the interval from last
ALSS to LT .48 h (OR=0.261, P=0.022).
Discussion
There is a lack of a clear definition of ACLF until the Asian
Pacific Association for the Study of the Liver consensus meeting in
2009. In China, where there is particularly high prevalence of
hepatitis B and huge population of hepatitis B patients, ACLF has
long been considered as a kind of severe viral hepatitis according
to the Viral Hepatitis Protection and Cure Guideline established
by the Chinese Infection and Hepatology Association. Although
ACLF is believed to be reversible, the reversibility depends on the
severity and nature of the acute insulting and the degree of
underlying chronic liver disease [4]. For ACLF-HBV patients with
‘high-grade’ MELD score ($30), resolving liver failure and
sustaining life can be hardly achieved [7]. Recent Studies
demonstrated extremely high short-term mortality of .90% in
ACLF patients with MELD scores $30 under conventional
medications [7,8]. ALSS treatment could slightly decrease the
mortality (68–91%) and therefore serve as a bridge to LT [7,8].
Thus LT was considered as the only curative therapy for these
patients. Since MELD score has been widely used for donor
organs allocation, ACLF patients usually have the priority to gain
a donor liver and receive emergency LT, which can effectively
resolve endotoxemia and liver failure before ACLF greatly
progresses [26]. As a result, the short-term and long-term survivals
were satisfactory for ACLF patients receiving emergency LT. This
indicated that LT should be considered as the first-line treatment
option in these patients. But timely LT is not always available
because of the donor shortage. The acute loss of liver function on
the basis of chronic hepatitis or cirrhosis can dramatically
Figure 1. Outcomes of all 126 ACLF patients with pre-transplant MELD $30. ALSS, artificial liver support system; DGM, downgraded MELD;
ELT, emergency liver transplantation; GVHD, graft versus host disease; MELD, model for end-stage liver disease; MODS, multi-organ dysfunction
syndrome; N-DGM, non-downgraded MELD.
doi:10.1371/journal.pone.0030322.g001
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and then causing severe complications such as infection and organ
failure [4,27]. Therefore, we performed ALSS as a salvage
treatment in all study patients who had no chance to receive
emergency LT as recommended by Artificial Liver Group,
Chinese Association of Infectious and Parasitic Diseases and
Chinese Medical Association.
For patients receiving ALSS treatment prior to LT, only those
with decreased MELD score showed encouraging long-term
survival after LT. Persistently high MELD score before LT was
identified as the major independent risk factor of both early death
and overall death. ALSS could create good environment for the
self-regeneration of remained hepatocytes and thus led to great
amelioration in encephalopathy, total bilirubin, international
normalized ratio and creatinine, as well as a decrease in MELD
score [11,14]. In this sense, pre-transplant salvage treatment could
be considered as ‘valid’ and ‘invalid’ in patients with decreased
MELD and non-decreased MELD, respectively. For patients with
non-reduced MELD, high levels of circulating endotoxins could be
even elevated throughout the transplantation procedure and
during the early post-transplant period, and then contribute to
high morbidity and mortality [28]. For patients with decreased
MELD, ALSS treatment improved patient conditions and
enhanced the surgical tolerance. Although their waiting time was
much longer than patients receiving emergency LT, patients
experienced uneventful procedure during peri-operative period
and showed comparable incidence of post-transplant complica-
tions and low early mortality. Since a reduced MELD score played
Figure 2. Comparison of patient cumulative survivals. Kaplan-Meier analysis was used to compare survivals between patients underwent LDLT
and those received DDLT (A), patients with acute exacerbation of chronic hepatitis B and those with acute deterioration of cirrhosis (B), ELT group,
DGM group and N-DGM group (C), patients with PMPM score ,21.4 and those with PMPM score .21.4 (D). LDLT, living donor liver transplantation;
DDLT, deceased donor liver transplantation; ELT, emergency liver transplantation; DGM, downgraded MELD; N-DGM, non-downgraded MELD; PMPM,
post-transplant model for predicting mortality.
doi:10.1371/journal.pone.0030322.g002
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potential influence factors of downgrading MELD was essential.
Age, hepatic encephalopathy, hepatorenal syndrome, infection
and treatment interval (from last ALSS to LT) were found to be
associated with reduction of MELD score. The cut-off values of
age and treatment interval were chosen according to the clinical
experience. Old age has been considered as a risk factor of patient
prognosis after LT especially in patient with liver failure [29].
However, the impact of old age on the efficacy of ALSS has been
rarely studied and need clarification in the further research. As
well known, ALSS could only substitute a few elementary liver
functions but not replace the entire spectrum of hepatic function.
It is beneficial to ameliorate the microenvironment of the liver, but
the function recovery is basically dependent on the self-
regeneration of remained hepatocytes. In this study, hepatic
encephalopathy, hepatorenal syndrome and infection, which
reflected clinical severity of end-stage liver disease, were not
independent influence factors. Consequently, the ability of ALSS
to improve the MELD score might not be determined by the
severity of underlying diseases. For ACLF patients with ‘high-
grade’ MELD scores, whose livers have virtually little chance of
self-regeneration [7], our results revealed the efficacy of ALSS was
more likely determined by the therapeutic timing. The multivar-
iate analysis showed long treatment interval (last ALSS to LT
.48 h) played central role in the reduction of MELD score. A
recent study investigated the dynamic change of total bilirubin,
international normalized ratio and creatinine levels after ALSS,
showing a significant improvement at 24 h, however, deterioration
at 72–120 h post-ALSS [11] in these parameters. Thus many
patients received several sessions of ALSS treatment before LT
because their conditions deteriorated soon after one session of
salvage treatment. These results suggested that consecutive
sessions of ALSS were indeed effective in bridging critically ill
patients to LT. An appropriate or even additional ALSS treatment
within 48 h prior to LT was beneficial for improving patient’s
condition and downgrading MELD, thus further reducing the
post-transplant mortality.
Hepatorenal syndrome was found to be another independent
risk factor of early deaths. Hepatorenal syndrome occurs
predominantly in advanced cirrhosis and also develops in severe
liver failure, and may accompany the worst prognosis among all
the complications of cirrhosis. There has been a consensus that
pre-transplant renal dysfunction was a strong predictor of poor
prognosis after LT, especially in patients with high MELD score
[15,30,31]. In some LT candidates with severe kidney impairment,
renal function maybe deteriorated after LT and combined liver
kidney transplantation should be considered [15,32]. Our results
were consistent with the previous studies that high prevalence of
hepatorenal syndrome contributed to the high incidence of post-
transplant acute kidney injury and high mortality. The findings
Table 2. COX regression for pre-transplant influence factors of patient death.
Univariable analysis Multivariable analysis
Risk ratio (95% CI) P Risk ratio (95% CI) P
Early mortality (,30 d)
N-DGM (vs. ECT and DGM) 3.112 (1.331–7.273) 0.009 2.426 (1.002–5.881) 0.049
Delta-MELD 1.086 (1.006–1.173) 0.035
Hepatorenal syndrome 3.136 (1.404–7.005) 0.005 2.422 (1.047–5.600) 0.039
Infection 2.372 (1.065–5.281) 0.034
Serum sodium 0.927 (0.875–0.981) 0.008
Overall mortality
N-DGM (vs. ECT and DGM) 3.196 (1.623–6.294) 0.001 3.209 (1.499–6.869) 0.003
Delta-MELD 1.083 (1.018–1.152) 0.011
Hepatorenal syndrome 2.015 (1.050–3.867) 0.035
Serum sodium 0.938 (0.895–0.984) 0.009
Abbreviations: CI, confidence interval; DGM, downgraded MELD; ELT, emergency liver transplantation; MELD, model for end-stage liver disease; N-DGM, non-
downgraded MELD.
doi:10.1371/journal.pone.0030322.t002
Table 3. Logistic regression for influence factors of downgrading MELD.
Univariable analysis Multivariable analysis
Odds ratio (95% CI) P Odds ratio (95% CI) P
Age .40 y (vs. #40 y) 0.292 (0.112–0.759) 0.012 0.240 (0.076–0.760) 0.015
Hepatic encephalopathy (yes vs. no) 0.400 (0.162–0.986) 0.047
Hepatorenal syndrome (yes vs. no) 0.250 (0.088–0.708) 0.009
Infection (yes vs. no) 0.250 (0.088–0.708) 0.009
Interval from last ALSS to LT .48 h (vs. #48 h) 0.307 (0.106–0.888) 0.029 0.261 (0.083–0.824) 0.022
Abbreviations: ALSS, artificial liver support system; CI, confidence interval; MELD, model for end-stage liver disease; LT, liver transplantation.
doi:10.1371/journal.pone.0030322.t003
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was of vital importance for reducing the morbidity and mortality
in patients with ACLF.
In the present study, we found several potential influencing
factors including the quality of donors, HBV DNA load and
cirrhosis background did not affect the patient survival. We have
previously reported that moderately steatotic liver grafts provide
adequate function in the first phase after transplantation and can
be used for transplantation [17]. The shortage of donor organs has
required us to use moderately but not severe steatotic liver grafts in
order to expand the donor pool. HBV DNA load has been
reported to be a predictor of poor prognosis among ACLF patients
with high MELD score [8]. However, no good prognostic ability
was seen among those critically ill patients after liver transplan-
tation. Since lamivudine combined with low-dose intramuscular
hepatitis B immunoglobulin therapy were routinely used in our
center, HBV has been well controlled during the peri-operative
period and the HBV recurrent rate has largely been reduced [13].
Other prognostic factors rather than HBV DNA load may play
key roles in patient survival. Post-transplant model for predicting
mortality (PMPM) was proven once again to be a good survival
predictor even in this special study population [22]. In our centre,
we use PMPM as an alarm bell for early recognition and
prediction of poor outcome.
There were several limitations in this study. First, the endotoxin
levels were not measured in all study population and thus not
included in the data analysis. The comparison of circulating
endotoxin levels during the peri-operative period among ELT,
DGM and N-DGM groups, and the possible negative effect of
high circulating endotoxin level on patient outcomes should be
further evaluated in ACLF patients with high MELD score.
Second, this study was limited in a Chinese population with severe
hepatitis B. These study results should be further verified in a
heterogeneous Western population with a relatively low incidence
of hepatitis B. Third, this was not a randomized study because the
selection of patients for emergency LT had to follow the organ
allocation system. Only the critically ill patients received timely
ALSS treatment which was limited by the availability of plasma
and machine. Therefore, there were several confounding variables
which may affect the results. A randomized study between groups
that have and do not have prompt ALSS (within 48 h prior to LT)
to reduce MELD scores should be conducted to verify our results.
In summary, for ACLF patients with ‘high’ MELD score,
emergency LT was the choice and reduction of the MELD score
before LT was effective in improving the patient prognosis. An
appropriate ALSS treatment within 48 h prior to LT can be
beneficial.
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